Disclosure: Long REPR
We have accumulated shares of REPR - Repromed Medical Systems during the market slaughter. This is a fast growing manufacuter of medical equipment in the USA. Their leading product is the FREEDOM60® Syringe Infusion System. Sales are booming and they are adding and hiring for new positions. The P/E is very low on this stock and growth should continue. I am looking forward to the new earnings report due around Oct 14 or so. The stock has traded as low as 21 cents during the market downturn.
Disclosure: Long REPR |
Paul SaadSenior Manager, Paul Saad and Associates, LLC Archives
May 2020
Categories |